Search NASA⌕ Search

SEARCH · Search NASA

Results for “THORIUM 227”

Search indexed NASA NTRS and DOE OSTI research on propulsion, heat transfer, battery materials and energy systems. Follow report and document links to the original sources.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

11 records
All sourcesNASA NTRSDOE OSTI
DOE OSTI2016

Nuclear Data Sheets for A = 227

The evaluated spectroscopic data are presented for ten known nuclides of mass 227 (Po, At, Rn, Fr, Ra, Ac, Th, Pa, U, Np). For {sup 227}Po, {sup 227}At, {sup 227}Rn, {sup 227}Pa, {sup 227}U and {sup 227}Np nuclei, only the ground-state information is available. Their decay characteristics are mostly unknown. Levels in {sup 227}Fr are known only from the decay of {sup 227}Rn to {sup 227}Fr. This decay scheme at present cannot be normalized to deduce γ intensities per 100 decays due to lack of knowledge about multipolarities of many low-energy transitions. The levels in {sup 227}Ra, {sup 227}Ac and {sup 227}Th are known from several decays and reactions, including particle-transfer data for {sup 227}Ra and {sup 227}Ac. The decay scheme of {sup 227}Ra to {sup 227}Ac was last studied in 1971 using small Ge detectors. Improved γ-ray intensity data need to be obtained with a better γ-detection system. The datasets for {sup 227}Ac have undergone extensive revisions, including detailed data for 231Pa α decay from 1986BaYK report, and single-proton transfer data from 1986MaYU thesis. High-spin (J>13/2 or so) structures are known only for 227Th. Level lifetime data are quite scarce for all the nuclides in this mass chain, thus limiting the knowledge of reduced transition probabilities. Band structures for {sup 227}Fr, {sup 227}Ra, {sup 227}Ac and {sup 227}Th are known in detail, together with evidence of weak octupole deformation and consequent parity-doublet structures. This evaluation was carried out as part of a joint IAEA-ICTP workshop for Nuclear Structure and Decay Data, organized and hosted by the IAEA, Vienna and ICTP, Trieste, March 24–28, 2014. The evaluation work was coordinated by B. Singh (McMaster). This work supersedes previous A=227 evaluation (2001Br31) published by E. Browne which covered literature before May 2001.

73 NUCLEAR PHYSICS AND RADIATION PHYSICS↗
DOE OSTI2019

Recommended Nuclear Data for the Production of Selected Therapeutic Radionuclides

Increasing interest in the treatment of human disease by means of targeted radionuclide-based therapies requires an accurate understanding of achievable yields and quantification of realisable degrees of purity. Important studies within a more extensive Coordinated Research Project of the International Atomic Energy Agency (IAEA CRP) have included in-depth assessments and evaluations of all available measured cross-section data for ten nuclear reactions leading to the formation of 131 Cs, 131 Ba, 225 Ac, 225 Ra, 227 Th, 227 Ac, 230 U and 230 Pa for various on-going and proposed therapeutic applications in nuclear medicine. Equivalent studies were also undertaken of possible reactions to produce the 178W /low-spin 178m Ta generator system that has been clinically applied in diagnosis by means of SPECT - these particular cross-section studies and recommendations are included in this paper for completeness. All available measured data have been critically reviewed and assessed to produce statistically consistent datasets. Selected datasets have been fitted by a least-squares method with Padé approximations of variable order to evaluate the production cross sections and corresponding uncertainties. New measurements have been made in some instances, and reported data have been adjusted to accommodate new nuclear decay or monitor reaction data which altered the original reported quantities adversely. Insufficient measured data are available in many cases to permit a reliable evaluation of cross sections, and these instances are discussed. Finally, recommended therapeutic radionuclide production reaction data and their uncertainties are available on the Web page of the IAEA Nuclear Data Section at www-nds.iaea.org/radionuclides/ and also at the IAEA medical portal www-nds.iaea.org/medportal/.

63 RADIATION, THERMAL, AND OTHER ENVIRON. POLLUTAN↗
DOE OSTI2018

Solution Thermodynamics and Kinetics of Metal Complexation with a Hydroxypyridinone Chelator Designed for Thorium-227 Targeted Alpha Therapy

In this study, the solution chemistry of a chelator developed for 227 Th targeted alpha therapy was probed. The compound of interest is an octadentate ligand comprising four N-methyl-3-hydroxy-pyridine-2-one metal-binding units, two tertiary amine groups, and one carboxylate arm appended for bioconjugation. The seven pK a values of the ligand and the stability constants of complexes formed with Th(IV), Hf(IV), Zr(IV), Gd(III), Eu(III), Al(III), and Fe(III) were determined. The ligand exhibits extreme thermodynamic selectivity toward tetravalent metal ions with a ca. 20 orders of magnitude difference between the formation constant of the Th(IV) species formed at physiological pH, namely [ThL] - , and that of its Eu(III) analogue. Likewise, log β 110 values of 41.7 ± 0.3 and 26.9 ± 0.3 (T = 25 °C) were measured for [ThL] - and [Fe III L] 2- , respectively, highlighting the high affinity and selectivity of the ligand for Th ions over potentially competing endogenous metals. Single crystal X-ray analysis of the Fe(III) complex revealed a dinuclear 2:2 metal:chelator complex crystallizing in the space group P1 - . The formation of this dimeric species is likely favored by several intramolecular hydrogen bonds and the protonation state of the chelator in acidic media. L III edge EXAFS data on the Th(IV) complexes of both the ligand and a monoclonal antibody conjugate revealed the expected mononuclear 1:1 metal:chelator coordination environment. This was also confirmed by high resolution mass spectrometry. Lastly, kinetic experiments demonstrated that labeling the bioconjugated ligand with Th(IV) could be achieved and completed after 1 h at room temperature, reinforcing the high suitability of this chelator for 227 Th targeted alpha therapy.

37 INORGANIC, ORGANIC, PHYSICAL, AND ANALYTICAL CH↗
DOE OSTI2023

Evaluation of Candidate Theranostics for 227 Th/ 89 Zr Paired Radioimmunotherapy of Lymphoma

227 Th is a promising radioisotope for targeted α-particle therapy. It produces 5 α-particles through its decay, with the clinically approved 223 Ra as its first daughter. There is an ample supply of 227 Th, allowing for clinical use; however, the chemical challenges of chelating this large tetravalent f-block cation are considerable. Using the CD20-targeting antibody ofatumumab, we evaluated chelation of 227 Th 4+ for α-particle–emitting and radiotheranostic applications. Methods: We compared 4 bifunctional chelators for thorium radiopharmaceutical preparation: S-2-(4-Isothiocyanatobenzyl)-1,4,7,10-tetraazacyclododecane tetraacetic acid (p-SCN-Bn-DOTA), 2-(4-isothicyanatobenzyl)-1,2,7,10,13-hexaazacyclooctadecane-1,4,7,10,13,16-hexaacetic acid (p-SCN-Bn-HEHA), p-isothiacyanatophenyl-1-hydroxy-2-oxopiperidine-desferrioxamine (DFOcyclo*-p-Phe-NCS), and macrocyclic 1,2-HOPO N-hydroxysuccinimide (L804-NHS). Immunoconstructs were evaluated for yield, purity, and stability in vitro and in vivo. Tumor targeting of the lead 227 Th-labeled compound in vivo was performed in CD20-expressing models and compared with a companion 89 Zr-labeled PET agent. Results: 227 Th-labeled ofatumumab-chelator constructs were synthesized to a radiochemical purity of more than 95%, excepting HEHA. 227 Th-HEHA-ofatumumab showed moderate in vitro stability. 227 Th-DFOcyclo*-ofatumumab presented excellent 227 Th labeling efficiency; however, high liver and spleen uptake was revealed in vivo, indicative of aggregation. 227 Th-DOTA-ofatumumab labeled poorly, yielding no more than 5%, with low specific activity (0.08 GBq/g) and modest long-term in vitro stability (<80%). 227 Th-L804-ofatumumab coordinated 227 Th rapidly and efficiently at high yields, purity, and specific activity (8 GBq/g) and demonstrated extended stability. In vivo tumor targeting confirmed the utility of this chelator, and the diagnostic analog, 89 Zr-L804-ofatumumab, showed organ distribution matching that of 227 Th to delineate SU-DHL-6 tumors. Conclusion: Commercially available and novel chelators for 227 Th showed a range of performances. The L804 chelator can be used with potent radiotheranostic capabilities for 89 Zr/ 227 Th quantitative imaging and α-particle therapy.

227Th↗
DOE OSTI2019

The application of poorly crystalline silicotitanate in production of 225 Ac

Actinium-225 ( 225 Ac) can be produced from a Thorium-229/Radium-225 ( 229 Th/ 225 Ra) generator, from high/low energy proton irradiated natural Thorium or Radium-226 target. Titanium based ion exchanger were evaluated for purification of 225 Ac. Poorly crystalline silicotitanate (PCST) ion exchanger had high selectivity for Ba, Ag and Th. 225 Ac was received with trace amounts of 227 Ac, 227 Th and 223 Ra, and the solution was used to evaluate the retention of the isotopes on PCST ion exchanger. Over 90% of the 225 Ac was recovered from PCST, and the radiopurity was >99% (calculated based on 225 Ac, 227 Th, and 223 Ra). The capacity of the PCST inorganic ion exchange for Barium and 232 Th was determined to be 24.19 mg/mL for Barium and 5.05 mg/mL for Thorium. PCST ion exchanger could separate 225 Ac from isotopes of Ra and Th, and the process represents an interesting one step separation that could be used in an 225 Ac generator from 225 Ra and/or 229 Th. Capacity studies indicated PCST could be used to separate 225 Ac produced on small 226 Ra targets (0.3–1 g), but PCST did not have a high enough capacity for production scale Th targets (50–100 g).

43 PARTICLE ACCELERATORS↗
DOE OSTI2020

Thorium chelators for targeted alpha therapy: Rapid chelation of thorium-226

We report one of the main challenges in targeted alpha therapy is assuring delivery of the α-particle dose to the targeted cells. Thus, it is critical to identify ligands for α-emitting radiometals that will form complexes that are very stable, both in vitro and in vivo. In this investigation, thorium-227 (t 1/2 = 18.70 days) chelation of ligands containing hydroxypyridinonate (HOPO) or picolinic acid (pa) moieties and the stability of the resultant complexes were studied. Chelation reactions were followed by reversed-phased HPLC and gamma spectroscopy. Studies revealed that high 227 Th chelation yields could be obtained within 2.5 h or less with ligands containing four Me-3,2-HOPO moieties, 1 (83%) and 2 (65%), and also with ligands containing pa moieties, H 4 octapa 3 (65%) and H 4 py4pa 6 (87%). No reaction occurred with H 4 neunpa-p-Bn-NO 2 4, and the chelation reaction with another pa ligand H 4 pypa 5 gave inconsistent yields with a very broad radio-HPLC peak. The ligands spermine-(Me-3,2-HOPO) 4 1, H 4 octapa 3, and H 4 py4pa 6 had high stability (i.e., 87% of 227 Th still bound to the ligand) in phosphate-buffered saline at room temperature over a 6-day period. Preliminary studies with ligand 6 demonstrated efficient chelation of thorium-226 (t 1/2 = 30.57 min) when heated to 80°C for 5 min.

37 INORGANIC, ORGANIC, PHYSICAL, AND ANALYTICAL CH↗
DOE OSTI2016

Reactor production of Thorium-229

Limited availability of 229 Th for clinical applications of 213 Bi necessitates investigation of alternative production routes. In reactor production, 229 Th is produced from neutron transmutation of 226 Ra, 228 Ra, 227 Ac and 228 Th. Here, we evaluate irradiations of 226 Ra, 228 Ra, and 227 Ac targets at the ORNL High Flux Isotope Reactor.

22 GENERAL STUDIES OF NUCLEAR REACTORS↗
DOE OSTI2016

Engineered Recognition of Tetravalent Zirconium and Thorium by Chelator–Protein Systems: Toward Flexible Radiotherapy and Imaging Platforms

Targeted α therapy holds tremendous potential as a cancer treatment: it offers the possibility of delivering a highly cytotoxic dose to targeted cells while minimizing damage to surrounding healthy tissue. The metallic α-generating radioisotopes 225 Ac and 227 Th are promising radionuclides for therapeutic use, provided adequate chelation and targeting. In this work, we demonstrate a new chelating platform composed of a multidentate high-affinity oxygen-donating ligand 3,4,3-LI(CAM) bound to the mammalian protein siderocalin. Respective stability constants log β 110 = 29.65 ± 0.65, 57.26 ± 0.20, and 47.71 ± 0.08, determined for the Eu III (a lanthanide surrogate for Ac III ), Zr IV , and Th IV complexes of 3,4,3-LI(CAM) through spectrophotometric titrations, reveal this ligand to be one of the most powerful chelators for both trivalent and tetravalent metal ions at physiological pH. The resulting metal-ligand complexes are also recognized with extremely high affinity by the siderophore-binding protein siderocalin, with dissociation constants below 40 nM and tight electrostatic interactions, as evidenced by X-ray structures of the protein:ligand:metal adducts with Zr IV and Th IV . Finally, differences in biodistribution profiles between free and siderocalin-bound 238 Pu IV -3,4,3-LI(CAM) complexes confirm in vivo stability of the protein construct. The siderocalin:3,4,3-LI(CAM) assembly can therefore serve as a "lock" to consolidate binding to the therapeutic 225 Ac and 227 Th isotopes or to the positron emission tomography emitter 89 Zr, independent of metal valence state.

62 RADIOLOGY AND NUCLEAR MEDICINE↗
DOE OSTI2019

A Method for Understanding the Behaviour of Radioactive Decay Chains in Radiological Assessments - 19382

In many radiological groundwater pathway assessments, especially those where the assessment timescales of interest are relatively short (say a few thousand years or less), contributions to effective dose or radiological risk are dominated by radionuclides such as C-14, Cl-36 or I-129. Over longer timescales, additional radionuclides can also become key contributors to risk. In particular, members of the U-238 decay chain, notably Ra-226 and Pb-210, are likely to be key radionuclides. Other decay chains that can contribute significantly to dose or risk at times far into the future include Np-237 → U-233 → Th-229 and U-235 → Pa-231 → Ac-227. In this paper, a method is described for understanding decay chain behaviour in radiological assessments. The method uses a graphical approach in which the various modes of transport and decay in a system of connected compartments are represented as pathways between two nodes in a two-dimensional grid. Each pathway corresponds to a distinct transport and decay process. By so doing, the different transport and decay processes can be identified in a systematic way. The result is an algorithm for generating the contributions to effective dose or radiological risk without explicit solution of the transport equations. The method has been tested against numerical models and analytic solutions and found to give excellent agreement, while at the same time providing information about decay chain behaviour that would be difficult to obtain from a numerical assessment model. The power of the method is illustrated by applying it to some examples based on real repository concepts. (authors)

07 ISOTOPE AND RADIATION SOURCES↗
DOE OSTI2019

Gadolinium vanadate nanocrystals as carriers of α-emitters ( 225 Ac, 227 Th) and contrast agents

Gadolinium vanadate (GdVO 4 ) core and core +2 shell nanocrystals (NCs) were evaluated for in vitro retention of 225 Ac, 227 Th, and their first decay daughters, 221 Fr and 223 Ra, respectively. GdVO 4 NCs with a tetragonal crystal system (zircon-type) and spherical morphology were obtained by precipitation of GdCl 3 and Na 3 VO 4 using sodium citrate as a complexing agent. The growth of two nonradioactive GdVO 4 shells on both Gd( 225 Ac)VO 4 and Gd( 227 Th)VO 4 core NCs was demonstrated by an increase of 0.7 nm and 2 nm in the crystallite size, respectively. The maximum leakage of 225 Ac was 15% and 2.4% from core and core + 2 shells, whereas the leakage of 227 Th was 3% and 1.5%, respectively. The presence of two nonradioactive GdVO 4 shells increased the retention of 221 Fr and 223 Ra by 20% and 15% with respect to core NCs. Furthermore, a longitudinal proton relaxivity, r 1 = 0.9289 s –1 mM –1 , confirmed their potential application as contrast agents for magnetic resonance imaging. In summary, GdVO 4 NCs show promising capabilities as radionuclide carriers with partial retention of decay daughters and as contrast agents for theranostic applications.

73 NUCLEAR PHYSICS AND RADIATION PHYSICS↗
DOE OSTI2021

Transport model predictions of 225 Ac production cross sections via energetic p, d and α irradiation of 232 Th targets

Monte Carlo transport codes PHITS and MCNP6 were used to calculate the production cross sections of 225,227 Ac, 227,229 Th, 223,225 Ra, and 229,230,231 Pa via the bombardment of a 232 Th target with energetic protons, deuterons, and α-particles. The incident projectile energies ranged between 10 and 800 MeV/nucleon. When possible, the predicted production cross sections were compared with the available experimental data and other predictions. Here, the degree of the codes’ abilities to match the measured data provides a qualitative assessment of the codes’ abilities to predict data from similar, but unmeasured, projectile/target systems. In addition, a comparison between calculated cross sections and data may provide insight into possible improvements in the physics models employed by those transport codes.

223Ra↗